

XVII. БИБЛИОГРАФИЯ

1. Борисов, В. Здравен мениджмънт, 2005, 278 с.
2. Борисов, В. Стратегически здравен мениджмънт: философия и практика. 2006, 320 с.
3. Веков, Т. Лекарствена политика, реимбурсация и ценообразуване. С., Български кардиологичен институт, 2011, 268 с.
4. Воденичаров, Ц. Седемте разлики между медика и мениджъра. С., 2003, 80 с.
5. Воденичаров, Ц., Борисов, В, Глутникова, Зл. Ново обществено здравеопазване, 1998, 480 с.
6. Воденичаров, Ц., В Борисов., С. Гладиллов, К. Чамов, Д. Кръшков. Модел за ефективно развитие на българското здравеопазване. Здравен мениджмънт, 2005, 2, 5-14.
7. Гладиллов С., Делчева Е. Икономика на здравеопазването, София, Princers, 2009, 486.
8. Грънчарова, Г., П. Христова. Медицинска статистика, МУ Плевен, 2011, 255 с.
9. Димитрова, З., Г. Нешев. Фармакоикономика. Изд. Арсо, 2008, 205 с.
10. Класиране на участниците в процедурата за възлагане на обществена поръчка за доставка на лекарства по приложение № 1 към чл. 2, ал. 2 на Наредба № 34/25.11.2005 г. от Министерство на здравеопазването.
11. Наредба № 34/25.11.2005 г. за реда за заплащане от републиканския бюджет на лечението на българските граждани за заболявания, извън обхвата на задължителното здравно осигуряване.
12. Спецификации от конкурси за възлагане на обществена поръчка за доставка на лекарства по Приложение № 1 към чл. 2, ал. 2 на Наредба № 34/25.11.2005 г. от специализирани, многопрофилни и университетски болници.
13. Указание на Министъра на здравеопазването до директорите на държавни болници № 91-00-229/23.12.2010 г.
14. A Decade of Reversal: An Analysis of 146 Contraindicated Medical Practices, Mayo Clin Proc. August 2013;88(8):790-798.
15. Abegunde, D. Inefficiencies due to poor access to and irrational use of medicines to treat acute respiratory tract infection in children. World Health Report, 2010.
16. Adams, M., N. McCall, D. Gray. Economic analysis in randomized control trials. Medical Care, 30, 1992, 231-243.
17. Adamski, J., B. Godman., G. Ofierska-Sujkowska. Risk sharing arrangement for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Services Research, 10, 2010, 1-16.
18. Allanson, P., D. Petrie. On the choice of health inequality measure for the longitudinal analysis of income-related health inequalities. Health Economics, 22, 2013, № 3, 353-365.
19. Al, M. Cost-Effectiveness Acceptability Carves Revisited, Pharmaco Economics, 31, 2013, № 2, 93-100.
20. Anton, C., P. Nightingale, D. Adu. Improving prescribing using a rule based prescribing system. Quality and Safety in Health Care, 13, 2004, 186-190.

21. Ashworth, M., R. Lea, H. Gray. How are primary care organizations using financial incentives to influence prescribing? *J Publ Health*, 26, 2004, 48-51.
22. Baal, P., D. Meltzer, W. Brouwer. Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs. *PharmacoEconomics*, 31, 2013, № 5, 369-374.
23. Bae, S., S. Lee, E. Bae, S. Jang. Korean Guidelines for Pharmacoeconomic Evaluation. Consensus and Compromise, *PharmacoEconomics*, 31, 2013, № 4, 257-268.
24. Becker, D., D. Kessler, M. McClellan. Detecting Medicare abuse. *J Health Economics*, 24, 2005, 189-210.
25. Ben-Tovim, D., P. Hakendorf, M. Crotty. Applying risk adjusted cost-effectiveness (RAC-E) analysis to hospitals: Estimating the costs and consequences of variation in clinical practice. *Health Economics*, 22, 2013, № 6, 631-642.
26. Birch, S., C. Donaldson. Applications of cost benefit analysis to health care: Departures from welfare economic theory. *J Hith Econ*, 1987, 6, 211-225.
27. Black, A. Comparative costs of percutaneous transluminal coronary angioplasty and coronary bypass grafting in multivessel coronary artery disease. *Am J Cardiol*, 62, 1988, 809-811.
28. Bobinac, A. et al. Valuing QALY gains by applying a societal perspective. *Health Economics*, 2013, 10, 1272-1281.
29. Brown, A. Understanding Pharmaceutical Research Manipulation in the Context of Accounting Manipulation. *Journal of Law, Medicine, & Ethics* 41, 2013, № 3.
30. Cabrales, A., S. Jimenez-Martin. The determinants of pricing in pharmaceuticals: Are US prices really so high? *Health Economics*, 2013, 11, 1377-1397.
31. Cameron, A. Cost savings of switching consumption from originator brand medicines to generic equivalents. *World Health Report*, 2010.
32. Cameron, A. Medicine prices, availability and affordability in 36 developing and middle-income countries. *Lancet*, 373, 2009, 240-249.
33. Campbell, S. et al. Quality of primary care in England with the introduction of pay for performance. *N Engl J Med*, 2007, 357, 181-190.
34. Canning, D. Axiomatic foundations for cost-effectiveness analysis. *Health Economics*, 2013, 12, 1405-1416.
35. Chisholm D., D. Evans. Improving health system efficiency as a means of moving towards universal coverage. *World Health Report*, 2010.
36. Cockburn, R. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. *PLOS Medicine*, 2005, 2, 100-113.
37. Cutler, D., A. Deaton, A. Llerar-Muney. The determinants of mortality. *J Econ Perspectives*, 20, 2006, 97-120.
38. Cutler, D., W. Everett. Thinking outside the pillbox – medication adherence as a priority for health care reform. *N Engl J Med.*, 113, 2010, 1034-1045.
39. Dakin, H., S. Wordsworth. Cost-minimisation analysis vers us cost-effectiveness analysis, revisited. *Health Economics*, 22, 2013, № 1, 22-34.

40. Declercq, E., F. Menacker, M. McDorman. Rice in “no indicated risk” primary caesareans in the United States, 1991-2001: cross sectional analysis. *BMJ*, 330, 2005, 71-75.
41. Dixon, S. The use of condition specific outcome measures in economic appraisal. *Health economics*, 1995, 4, 255-264.
42. Donaldson, C., P. Shackley. *Economic evaluation. Oxford Textbook of Public Health.* Oxford, Oxford University Press, 1997.
43. Dondorp, A. Fake antimalarias in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarias. *TMSIH*, 2004, 9, 1241-1246.
44. Dowd, B., R. Feldman, W. Nersesian. Setting pay for performance targets: Do poor performers give up? *Health Economics*, 22, 2013, № 2, 168-179.
45. Drummond M., B. O'Brien, G. Stoddart, G. Torrance. *Methods for Economic Evaluation of Health Care Programmes.* Oxford University Press, 1997.
46. Drummond, M. *Principles of Economic Appraisal in Health Care.* Oxford, Oxford University Press, 1980.
47. Dylst, P., A. Vulto, S. Simoens. Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? *Health Policy*, 101, 2011, 146-152.
48. Dylst, P., S. Simoens. Does the market share of generic medicines influence the price level? A European analysis. *Pharmaco Economics*, 29, 2011, 875-882.
49. Dylst, P., S. Simoens. Generic medicine pricing policies in Europe: current status and impact. *Pharmaceuticals*, 2010, 3, 471-481.
50. DRG-based payment systems in low- and middle-income countries: Implementation experiences and challenges, Inke Mathauer and Friedrich Wittenbecher, World Health Organization 2012.
51. Drummond, M. Cost of Illness studies: a major headache. *PharmacoEconomics*, 1992, 2, 1-4.
52. Drummond, M. Welfare economics and cost-benefit analysis in health care. *Scottish Political Economy*, 1981, 28, 125-145.
53. Espin, J., J. Rovira, L. Garcia. *Experiences and Impact of European Risk-Sharing Schemes Focusing on Oncology Medicines.* European Commission, 2011.
54. Espin, J., J. Rovira. *Analysis of differences and commonalities in pricing and reimbursement systems in Europe.* European Commission, 2007.
55. Feldman, Y., R. Gauthier et T. Schuler. Curbing Misconduct in the Pharmaceutical Industry: Insights from Behavioral Ethics and the Behavioral Approach to Law. *Journal of Law, Medicine, & Ethics* 41, 2013, № 3.
56. Fischer, E. Medical care – is more always better? *N Engl J Med*, 349, 2003, 1665-1667.
57. Fischer, E. The implications of regional variation in Medicare spending. *Ann Int Med*, 138, 2003, 273-287.
58. Frayman, J., G. Van Hal, H. De Loof. Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium, Conference in Vienna, September 2011.

59. Forster, M. et P. Pertile. Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective. *Health Economics*, 2013, 12, 1507-1514.
60. Gagnon, M. A. Corruption of Pharmaceutical Markets: Addressing the Misalignment between Financial Incentives and Public Health. *Journal of Law, Medicine, & Ethics* 41, 2013, № 3.
61. Gandjour, A. Reference Pricing and Price Negotiations for Innovative New Drugs, Viable Policies in the Long Term? *PharmacoEconomics*, 31, 2013, № 1, 11-15.
62. Generic medicines: Essential contributors to the long term health of society, IMS, 2010.
63. Gerard, K. Cost-utility in practice: a policy markers guide to the state of the art. *Health Policy*, 21, 1992, 249-279.
64. Gold, M., J. Siegel, L. Russel, M. Weinstein. *Cost-effectiveness in Health and Medicine*. NY, Oxford University Press, 1996.
65. Gow, J., M. Strauss, A. Whiteside. The State of Health Economic Research in South Africa, *PharmacoEconomics*, 31, 2013, № 3, 251-255.
66. Gray, G. C. The Ethics of Pharmaceutical Research Funding: A Social Organization Approach. *Journal of Law, Medicine, & Ethics* 41, 2013, № 3.
67. Gray, J. Changing physicians prescribing behaviour. *Canad J Clin Pharmacol*, 13, 2006, 81-84.
68. Grieve, R., M. Sadique. Statistical methods for cost-effectiveness analyses that use observational data: A critical appraisal tool and review of current practice. *Health Economics*, 22, 2013, № 4, 486-500.
69. Hassard, T. *Understanding Biostatistics*, St. Louis, 1991.
70. Herr, A. Cost and technical efficiency of German hospitals: does ownership matter? *Health Economics*, 17, 2008, 1057-1071.
71. Hollingsworth, B. The measurement of efficiency and productivity of health care delivery. *Health Economics*, 17, 2008, 1107-1128.
72. Holloway, K., E. Dijk. Rational use of medicines. – In: *The World Medicine Situation*. Geneva, World Health Organization, 2010.
73. Hunt, B. et al. Evaluation on the Healthy Life Check programme: a vascular risk assessment service for community pharmacies in Leicester city. *J Publ Health*, 2013, 3, 440-446.
74. Karnon, J. et al. Applying risk adjusted cost-effectiveness (RAC-E) analysis to hospitals: Estimating the costs and consequences of variation in clinical practice. *Health Economics*, 2013, 6, 631-642.
75. Kanavos, P., W. Schurer, S. Vogler. The pharmaceutical distribution chain in the European Union: Structure and impact on pharmaceutical prices. Report, 2011.
76. Kanavos, P., E. Seeley, S. Vadoros. Tender systems for outpatient pharmaceuticals in the European Union: evidence from the Netherlands, Germany and Belgium, European Commission, 2009.
77. Landa, A. S. et C. Elliott. From Community to Commodity: The Ethics of Pharma-funded Social Networking Sites for Physicians. *Journal of Law, Medicine, & Ethics* 41, 2013, № 3.

78. Lazar, A. On the cardinal measurement of health inequality when only ordinal information is available on individual health status. *Health Economics*, 22, 2013, № 1, 114-118.
79. Ludbrook, A., K. Lowson, A. Steede. *Studies in Economic Appraisal in Health Care*. Oxford, Oxford University Press, 1986.
80. Leopold, C., S. Volger, A. Mantel-Teenwisse. Differences in external price referencing in Europe. – A descriptive overview. *Health Policy*, 104, 2012, 50-60.
81. Lichtenberg, F. The contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2010, Working Paper, № 3095.
82. Lindenauer, P. et al. Public reporting and pay for performance in hospital quality improvement. *N Engl J Med*, 2007, 356, 486-496.
83. Longworth, L., J. Youn, L. Bojke et al. When Does NICE Recommend the Use of Health Technologies Within a Programme of Evidence Development? *Pharmaco Economics*, 31, 2013, № 2, 137-150.
84. Lu, Y. Medicine expenditures. – In: *The World Medicines Situation*. Geneva, World Health Organization, 2010.
85. Luce, B., A. Elixhauser. Estimating costs in economic evaluation of medical technologies. *Int J Technology Assessment in Health Care*, 1990, 6, 57-75.
86. Marsh, K. et al. Prioritizing investments in public health: a multi-criteria decision analysis. *J Publ Health*, 2013, 3, 460-466.
87. *Market Review – The European Generic Medicines Markets*. European Generic Medicines Association, 2011.
88. Maynard, A. *Payment for performance*. Copenhagen, World Health Organization, Regional Office for Europe, 2008.
89. Mehrez, A., A. Gafni. Quality-adjusted life-years, utility theory and health years equivalents *Medical Decision Making*, 1989, 9, 142-149.
90. Meltzer, D. Accounting for future costs in medical cost-effectiveness analysis. *J Health Economics*, 1997, 16, 33-64.
91. *Medicaments generiques: plus d'1 milliard d'euros d'economie en 2009*, Caisse Nationale d'Assurance Maladie, 2009.
92. *Medicines use in primary care in developing and transitional countries*. Geneva, World Health Organization, 2009.
93. McDonagh, M., D. Smith, M. Goddard. Measuring appropriate use of acute beds. A systematic review of methods and results. *Health Policy*, 53, 2000, 157-184.
94. Miller, J.. From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy Practices through Accreditation, Certification, & Rating. *Journal of Law, Medicine, & Ethics* 41, 2013, № 3.
95. Mistry, H., J. Shen et J. Fox-Rushby. A systematic review and meta-analysis of willingness-to-pay values. *Health Economics*, 2013, 4, 428-450.
96. Norman, R., J. Hall, D. Street, R. Viney. Efficiency and equity: A stated preference approach. *Health Economics*, 22, 2013, № 5, 568-581.
97. O'Brien, B., S. Novosel, G. Torrance, D. Steiner. Assessing the economic value of a new antidepressant: a willingness-to-pay approach. *Pharmaco Economics*, 8, 1994, 34-35.

98. Oldridge, N., W. Furlong, D. Feeny, G. Torrance et al. Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction. *Am J Cardiol*, 72, 1993, 2, 154-161.
99. Oldroyd, J. Providing Healthcare for people with chronic illness: the views of Australian GPs. *Med J Australia*, 179, 2003, 30-33.
100. Oliver, K. et al. Who runs public health? A mixed-methods study combining qualitative and network analyses. *J Publ Health*, 2013, 3, 453-459.
101. Park, M. Provider payments and cast-containment – lessons from OECD countries. Geneva, World Health Organization, 2007.
102. Payne, K., M. McAlister et L. Davies. Valuing the economic benefits of complex interventions: when maximizing health is not sufficient. *Health Economics*, 2013, 3, 258-271.
103. Perrot, J. Performance incentives for health care providers. Geneva, World Health Organization, 2010.
104. Peery, A. F. et al., Burden of Gastrointestinal Disease in the United States, *Gastroenterology*, 2012, 143, № 5, 1179-1187.
105. Peterson, L. Does pay-for-performance improve the quality of health care? *Ann Int Med*, 145, 2006, 265-272.
106. Pharmaceuticals products – comparative price levels in 33 European countries in 2005, Eurostat, 2007.
107. Porter, M. The Strategy That Will Fix Health Care, Oct 2013, Harvard Business Review
108. Puig-Junoy, J. Impact of European pharmaceutical price. Regulation on generic price competition: A review. *Pharmaco Economics*, 28, 2010, 649-663.
109. Puig-Junoy, J., P. Garcia-Gomez, D. Casado-Marin. Free Medicines Thanks to Retirement: Moral Hazard and Hospitalization Offsets in an NHS. Tinbergen Institute Discussion Paper, 108, 2011, 1-33.
110. Ramsey, R. Activity-based costing for hospitals. *Hospital and Health Services Administration*, 39, 1994, 385-396.
111. Rogowski, W. An economic theory of the fourth hurdle. *Health Economics*, 22, 2013, № 5, 600-610.
112. Rose, L. Patient Advocacy Organizations: Institutional Conflicts of Interest, Trust, and Trustworthiness. *Journal of Law, Medicine, & Ethics* 41, 2013, no. 3.
113. Rotter, T., Kinsman, L., James, E.L., et al. Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs. *Cochrane Database of Systematic Reviews* 2010, Issue 3. Art. No. CD006632. DOI: 10.1002/14651858.CD006632.pub2.
114. Sackett, D. Evaluation of health services. *N. Engl. J. Med.*, 1980, 296, 732-737.
115. Sah, S. et A. Fugh-Berman. Physicians Under the Influence: Social Psychology and Industry Marketing Strategies. *Journal of Law, Medicine, & Ethics* 41, 2013, № 3.
116. Sackett, D., R. Haynes, G. Guyatt, P. Tugwell. *Clinical epidemiology: a basic science for clinical medicine*. Boston, Little Brown & Comp., 1991.

117. Schulenburg, F., S. Vondros, P. Kanavos. The effects of a market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors. *Health Economic Review*, 2011, 1, 1-8.
118. Sculpher, M., P. Seed, R. Henderson, M. Buxton et al. Health service costs of coronary angioplasty and coronary artery bypass surgery: the randomized intervention treatment of angina (RITA) trial. *Lancet*, 344, 1994, 927-930.
119. Siddiqi, S. Framework for assessing governance of the health system in developing countries: gateway to good governance. *Health Policy*, 90, 2009, 13-25.
120. Simoens, S. Addressing escalating health care costs in ageing populations by increasing generic medicine utilization. *J Gener Med*, 2011, 8, 150-156.
121. Simoens, S. Health care sustainability and generic substitution. *Hospital Pharmacy Europe*, 55, 2011, 32-34.
122. Simoens, S., S. De Coster. Potential savings from increased substitution of generic for originator medicines in Europe. *J Gener Med*, 2008, 4, 43-45.
123. Skipper, N. On the demand for prescription drugs: heterogeneity in price responses. *Health Economics*, 22, 2013, № 7, 857-879.
124. Schiff, G. et al. Principles of conservative prescribing. *Archives of Internal Medicine* 2011,171,1433-30.
125. Sismondo, S. Key Opinion Leaders and the Corruption of Medical Knowledge: On What the Sunshine Act Will and Won't Cast Light On. *Journal of Law, Medicine, & Ethics* 41, № 3, 2013.
126. Smith, P. Incorporating financial protection into decision rules for publicly financed healthcare treatments. *Health Economics*, 2013, 2, 180-193.
127. Stoler, A. et D. Meltzer. Mortality and Morbidity risks and economic behavior. *Health Economics*, 2013, 2, 132-143.
128. Thorn et al. Timely and Complete Publication of Economic Evaluations Alongside Randomized Controlled trials *PharmacoEconomics*, 2013, 31, 77-85.
129. Torrance, G. Measurement of health state utilities for economic appraisal. *J. Health Economics*, 1986, 5, 1-30.
130. Weinstein, M. Economic assessment of medical practices and technologies. *Medical Decision-Making*, 1981, 4, 309-330.
131. Wilde, E. Do emergency medical system response times matter for health outcomes? *Health Economics*, 2013, 7, 790-806.